CV Science

Emmanuel GARCION PhD, HDR

Course and current status

2017- Group Leader – INSERM U1232 - Team 17 - GLIAD <<Design and Application of Innovative Local treatments in Glioblastoma>> - Cancer and Immunology Research Centre Nantes-Angers - Institut de Biologie en Santé – University of Angers

http://www.crcina.org/recherche/departement-3-nohmad/equipe-17-design-and-application-of-innovative-local-treatments-in-glioblastoma/

2^ndClass Research Director, DR2 Inserm (French NIH) (Since October 1^st, 2016)

Supervisor of the Platform for Cellular and Molecular Analysis (PACeM) - University of Angers

http://www.univ-angers.fr/fr/recherche/poles-et-unites/services-communs-de-recherche/pacem.html

2005-2012 1^stClass Research Associate, CR1 Inserm (Neuro-Oncology and Nanomedicines), Inserm U1066 - Angers, France

2004 HDR "Habilitation à Diriger des Recherches" - University of Angers - Angers, France

2002-2004 Research Associate (Neuro-Oncology and Nanomedicines), Inserm ERIT-M 0104 - Angers, France

1998-2001 Research Associate (Developmental Neurobiology), University of Cambridge, Wellcome-CRC Institute & Brain Repair Center - Cambridge, UK

1997 PhD in Neurosciences, University of Pierre & Marie Curie (UPMC) - Paris, France

1994-1997 PhD student (Neuro-immunology), Inserm U298 - Angers, France

Scientific summary

Topic: Design and Application of Innovative Local treatments in Glioblastoma 

Keywords: Glioblastoma; Loco-regional drug delivery; Nanobiotechnologies; Bio-Implants; Radiopharmaceuticals & Radiobiology; Therapeutic proteins; Genetics & RNAi; MedTech - Medical Technology

Special Interests:

• Targeting cancer stem-like cells in glioblastoma
• Loco-regional confinement and subcellular routing of anticancer drugs
• miRNA, RNAi, genomic and radiation résistance

The failure of the treatment of certain solid tumors, a typical example of which is glioblastoma (GB), resulted from tumor resistance and suboptimal administration of the active principle. In the continuity of my work on the loco-regional administration of micro-nanomedicines, some of which have brought a significant preclinical benefit, my goal is now to better understand these systems at the nano-biological interface for therapeutic significance in humans. Two approaches targeting tumor cells infiltrated into the central nervous system are studied.

The first combines nano-vectorised internal radiation therapy with in situ radiosensitization. The choice of radiopharmaceuticals combined with the modalities of application and confinement or intratumoral targeting is particularly studied. The automation of formulation processes as well as the evaluation of dosimetry in correlation with biological responses are among the milestones of this project. The "nano-particle" and more recently "protein" targeting of the microRNA machinery involved in radioresistance is also investigated. A close link with the characterization of new targets from molecular genetic analysis is also realized (eg. fusion genes).

The second approach focus on the intraoperative implantation of bio-interactive deposit formulations for the control of fate, trapping and elimination of cancer cells. Based on our expertise in the development of innovative formulations releasing bioactive molecules (eg. therapeutic proteins), the goal of this work is through biopolymer implants (eg. sponges, nanofibers, etc…) to exert homing of tumor cells in a controlled and confined area before elimination. The SDF1 / CXCR4 axis is particularly investigated.

By its fundamental and technological aspects, this project opens the perspective of a loco-regional medicine (especially micro-nanomedicine) optimized for the treatment of GB but also other cancers. Several biomedical and technological bolts concerning the in vivo behavior of particulate vectors and the targeting of key tumor entities will be unlocked. New strategies to eliminate radiation-resistant cell contingents will be proposed.